Legato Capital Management LLC Purchases Shares of 13,335 Inari Medical, Inc. (NASDAQ:NARI)

Legato Capital Management LLC bought a new position in Inari Medical, Inc. (NASDAQ:NARI - Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The firm bought 13,335 shares of the company's stock, valued at approximately $681,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Jennison Associates LLC lifted its position in shares of Inari Medical by 11.8% in the 4th quarter. Jennison Associates LLC now owns 1,763,258 shares of the company's stock worth $90,014,000 after purchasing an additional 186,617 shares during the period. R Squared Ltd purchased a new position in Inari Medical during the 4th quarter valued at about $45,000. KBC Group NV lifted its position in Inari Medical by 31.5% during the 4th quarter. KBC Group NV now owns 2,333 shares of the company's stock valued at $119,000 after acquiring an additional 559 shares during the period. AMI Asset Management Corp purchased a new position in Inari Medical during the 4th quarter valued at about $1,651,000. Finally, GAMMA Investing LLC lifted its position in Inari Medical by 66.8% during the 4th quarter. GAMMA Investing LLC now owns 1,963 shares of the company's stock valued at $100,000 after acquiring an additional 786 shares during the period. 90.98% of the stock is owned by hedge funds and other institutional investors.

Inari Medical Stock Performance

Shares of NARI stock remained flat at $79.93 during trading hours on Friday. 1,012,995 shares of the stock were exchanged, compared to its average volume of 2,432,933. The business has a 50 day moving average of $69.07 and a two-hundred day moving average of $54.31. Inari Medical, Inc. has a 52-week low of $36.73 and a 52-week high of $79.97. The firm has a market capitalization of $4.68 billion, a price-to-earnings ratio of -59.21 and a beta of 1.02.

Analyst Ratings Changes

A number of brokerages recently issued reports on NARI. Wells Fargo & Company reissued an "equal weight" rating and set a $80.00 price target (up from $65.00) on shares of Inari Medical in a research report on Tuesday, January 7th. Truist Financial lifted their price target on shares of Inari Medical from $50.00 to $63.00 and gave the company a "hold" rating in a research report on Wednesday, December 18th. BTIG Research reissued a "neutral" rating on shares of Inari Medical in a research report on Wednesday, January 8th. Oppenheimer initiated coverage on shares of Inari Medical in a research note on Tuesday, December 17th. They set an "outperform" rating and a $75.00 price objective for the company. Finally, Needham & Company LLC restated a "hold" rating on shares of Inari Medical in a research note on Tuesday, October 29th. Twelve analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $68.00.

Insider Transactions at Inari Medical

In other news, CEO Andrew Hykes sold 3,000 shares of Inari Medical stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $55.29, for a total value of $165,870.00. Following the completion of the sale, the chief executive officer now directly owns 439,310 shares in the company, valued at $24,289,449.90. The trade was a 0.68 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director William Hoffman sold 200,000 shares of the business's stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $60.47, for a total transaction of $12,094,000.00. Following the sale, the director now owns 238,987 shares of the company's stock, valued at $14,451,543.89. This trade represents a 45.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 323,000 shares of company stock worth $18,669,070 over the last three months. 10.60% of the stock is currently owned by company insiders.

About Inari Medical

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.